Q3 2024 EPS Estimates for Krystal Biotech, Inc. Lifted by Analyst (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Investment analysts at William Blair boosted their Q3 2024 EPS estimates for shares of Krystal Biotech in a research note issued to investors on Monday, May 6th. William Blair analyst T. Lugo now expects that the company will earn $0.63 per share for the quarter, up from their previous estimate of $0.41. William Blair has a “Outperform” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $1.82 per share. William Blair also issued estimates for Krystal Biotech’s Q4 2024 earnings at $0.75 EPS, FY2024 earnings at $1.91 EPS, Q1 2025 earnings at $1.41 EPS, Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.61 EPS, Q4 2025 earnings at $1.28 EPS, FY2025 earnings at $5.58 EPS, FY2026 earnings at $5.26 EPS and FY2027 earnings at $9.70 EPS.

A number of other research firms have also weighed in on KRYS. Citigroup raised their target price on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Guggenheim upped their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Finally, HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research note on Monday. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and a consensus price target of $171.00.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $157.68 on Thursday. Krystal Biotech has a 1-year low of $86.03 and a 1-year high of $189.97. The business has a 50 day simple moving average of $168.76 and a two-hundred day simple moving average of $134.27. The stock has a market capitalization of $4.50 billion, a PE ratio of 1,971.25 and a beta of 0.91.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The firm had revenue of $45.25 million for the quarter, compared to analysts’ expectations of $47.37 million. Krystal Biotech’s revenue was up 452400.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.76) EPS.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the transaction, the chief accounting officer now owns 12,936 shares in the company, valued at approximately $2,145,823.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Kathryn Romano sold 5,000 shares of Krystal Biotech stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Insiders sold a total of 38,087 shares of company stock valued at $6,210,591 over the last 90 days. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of KRYS. State Board of Administration of Florida Retirement System raised its position in Krystal Biotech by 18.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company’s stock valued at $1,300,000 after purchasing an additional 1,140 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Krystal Biotech by 9.0% in the first quarter. ProShare Advisors LLC now owns 5,865 shares of the company’s stock valued at $1,044,000 after acquiring an additional 486 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Krystal Biotech in the first quarter worth about $291,000. Sei Investments Co. lifted its stake in Krystal Biotech by 128.3% in the first quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock worth $6,005,000 after acquiring an additional 18,968 shares during the period. Finally, Swiss National Bank grew its holdings in Krystal Biotech by 0.8% during the 1st quarter. Swiss National Bank now owns 36,200 shares of the company’s stock worth $6,441,000 after acquiring an additional 300 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).